XML 13 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 86,580 $ 97,428
Short-term investments 37,535 102,791
Accounts receivable 6,586 6,170
Note receivable from Viking Therapeutics 3,207 4,782
Inventory 4,027 1,633
Other current assets 2,756 1,908
Total current assets 140,691 214,712
Deferred income taxes 133,486 189,083
Investment in Viking Therapeutics 17,339 29,728
Intangible assets, net 207,435 48,347
Goodwill 72,359 12,238
Commercial license rights, net 25,985 8,554
Property and equipment, net 1,826 372
Other assets 1,744 27
Total assets 600,865 503,061
Current liabilities:    
Accounts payable 2,757 4,083
Accrued liabilities 6,675 5,397
Current contingent liabilities 5,079 10,414
Current lease exit obligations 0 934
2019 convertible senior notes, net 210,115 201,985
Other current liabilities 1,505 8
Total current liabilities 226,131 222,821
2019 convertible senior notes, net 0 0
Long-term contingent liabilities 3,933 3,033
Other long-term liabilities 408 297
Total liabilities 230,472 226,151
Commitments and Contingencies
Equity component of currently redeemable convertible notes (Note 5) 32,138 39,628
Stockholders' equity:    
Common stock, $0.001 par value; 33,333,333 shares authorized; 20,898,889 and 19,949,012 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively 28 20
Additional paid-in capital 762,576 661,850
Accumulated other comprehensive income 3,652 4,903
Accumulated deficit (428,001) (429,491)
Total stockholders' equity attributable to Ligand Pharmaceuticals 338,255 237,282
Total liabilities and stockholders' equity $ 600,865 $ 503,061